Jared

[HedgeMind @HedgeMind]

$JMIA up ~15% after traded as low as $24.53 today. Currently at ~$32 is still ~$9 or 22% from ATH.

Very few hedge funds are in it as of Q3 except some quantitative hedge funds. 👇🏿

~90 institutional holders current hold ~24M shares, roughly 27% of shares outstanding.

[Jim Cramer @jimcramer]

If people do not do their own homework before they buy , they need to do so. As i said, it could be like Mercado Libre which i invested in even as people told me it was a phony (many years ago). I read Citron's work on it and thought it provocative.

[Grail @SmartMoney777]

$JMIA in Barron’s #2 biggest. Under NYSE Movers and Winners.

[Jared @doubleuptrading]

Sell the Snow long DDOG !!

[Ophir Gottlieb @OphirGottlieb]

$SNOW will trade at about $225.

Told ya. Everyone was excited for $80, but that was air.

[Ophir Gottlieb @OphirGottlieb]

$SNOW will trade at about $225.

Told ya. Everyone was excited for $80, but that was air.

[Stockonomist @Stockonomist]

#DDDD $DDDD 4D Pharma

Chart developing as I expected so far...

https://t.co/9Hr1XDmTVZ

[Renaissance Capital @IPOtweet]

Gene therapy developer 4D Molecular Therapeutics withdraws $100 million IPO $DDDD $IPO #IPO https://t.co/Uf9HYnDF9y

[4D pharma @4dpharmaplc]

@4dpharmaplc $DDDD #DDDD is pleased to announce full clinical benefit data from Part A of our trial of MRx0518 + #Keytruda. 42% disease control rate in heavily pre-treated #cancer patients blows away expectations. See the full data at https://t.co/rxcI3EqqbX

[Brian McGough @HedgeyeRetail]

#winning

[Ophir Gottlieb @OphirGottlieb]

$NLS Andrew is right about this, IMHO
https://t.co/WnGO0F5XrG

[Jared @doubleuptrading]

Get on the Nautilus bus!! NLS

[Brian McGough @HedgeyeRetail]

Oh the irony that riding my Peloton daily has helped me cope with the stress in being short $PTON. @HedgeyeRetailJM

[Jared @doubleuptrading]

Citron !!

[Brian McGough @HedgeyeRetail]

$RH #winning

[StockWarsAdventure @TheStockWars]

$FLDM has been the topic of several recent analyst reports. UBS Group upped price of Fluidigm from $12.00 to $16.00 and gave the company a "buy" rating in a report on Thursday. BidaskClub raised shares of Fluidigm from "hold" rating to a "buy" https://t.co/cgz4Rl472E...

[Dixie Bullington @dixielee1969]

$FLDM what a great swing, not even 2 months

[LK1K Crypto @LK1KTrades]

$FLDM News https://t.co/exa6UWCons

[Bertrand Delsuc @BertrandBio]

4D Pharma $DDDD +67% in London since Seres $MCRB ph3 data in C. Diff.
$DDDD IBS-C/D ph 2b data closing in (expected this quarter). Another boost for #microbiome bios? Not so sure at all, but possible. Tricky one based on the few available clinical data & the endpoint definition.

[Stockonomist @Stockonomist]

#DDDD $DDDD 4D Pharma

In October 2019 4D Pharma (Mkt Cap c.£40m) signed a headline $1Billion licencing deal with $240 Billion Merck (MSD) to develop vaccines... #justsaying

[Jared @doubleuptrading]

Clear winner PBI